odimma
Active Personalized Immunotherapy

An Next-Generation Personalised Immunotherapy Platform based on Artificial Intelligence and Synthetic DNA

Jean-Marc Limacher, MD

1ères Journées de recherche en ImmunoOncologie 13 et 14 mars 2025

ODI-2001 a solution for unmet medical needs

Medical Need	Immune Checkpoint Inhibitors' (ICIs) efficacy is limited to 20% of patients
Our Solution	Personalized double adjuvanted immunization platform based on Synthetic DNA and AI
Expected benefit	✓ Improved results of ICIs (anti-PD1) in their current indications ✓ anti-PD1 activity in not yet addressed indications
Technology advantages	Powerful immunization Short turn-around time Low COGs (Cost of Goods)
Clinical trial ready to go	GMP product ready Investigation center ready to go

ODI-2001: Odimma's proprietary synthetic DNA based personalized immunotherapy

ODI-2001 product is Classified by EMA as
Gene Therapy (ATMP)



- ✓ Proprietary formulation (WO2017060650)
- ✓ Two additional patents filed
- ✓ Neopepitope selection by AI (myNEO®)
- ✓ Manufacturing ready and supply chain in place
- ✓ Limited production cost for synthetic DNA
- ✓ No bacterial residues, no antibiotic resistance genes, no antibiotics
- ✓ MVA and anti-CTLA4 of produced in advance
- ✓ 7 weeks manufacturing process

DNA adsorption on MVA, double promoter allowing DNA expression both from nucleus and cytoplasm of MVA infected cells

ODI-2001 production process

2 Sequencing & Mapping

Sequencing and mapping of the mutations present in the tumor DNA

1 Collection

Collection of individual patient samples from blood and tumor in order to extract DNA

6 Delivery & subcutaneous administration of the solution



3 Neoantigens prediction by AI myNEO® prediction algorithm

4 Tailored synthetic DNA production

5 Packaging and shipping

Through an only 6 to 8 week process, Odimma is able to offer each patient an innovative and powerful personalized immunotherapy

ODI-2001 potentiates the most used immunotherapy (Anti-PD1)



Survival in mice melanoma model





ODI-2001 combined to anti-PD1 performs significantly better than anti-PD1 +/- anti-CTLA4 in an aggressive mice melanoma model
Significant activity in monotherapy

ODI-2001 performs better than competitive immunization technics including lipoplexed mRNA



B16F10 mice melanoma model, M30 neoepitope, monotherapy

ODI-2001: robust activity accross different aggresive cancer models

Metastatic colo-rectal carcinoma



ODI-2001 treatment increases the survival in advanced stage CT26 model

Triple negative breast cancer



ODI-2001 treatment increases mice survival in 4T1 model, the myNEO® prediction algorithm is key

Phase I/II in colorectal cancer

Indication	Advanced stage colorectal cancer
Investigator centers	Principal Investigator : Pr F. Ghiringhelli, Centre Georges François Leclerc, INSERM, Dijon, France Additional centers under investigation
Rationale	✓ICIs approved only in 15% of CRC (those with DNA instability) ✓Personalized immunotherapy with ODI-2001 aims to induce similar immunity in CRC patients with stable DNA (85% of cases) ✓Preclinical activity of ODI-2001 in CT26 colon cancer model ✓Phase I in 15 patients in 2025
Study extension with additional patient cohorts	Other settings, combination with ICIs (anti-PD1)

Phase I/II in colorectal cancer – Synopsis

- **Study population**
  - **Patients with metastatic or locally advanced non-operable colo-rectal cancer or pancreatic cancer**
  - **Responding to first-line chemotherapy (FOLFOX or FOLFIRINOX)**
- **Intervention**



  - **ODI 2001 given weekly for 6 weeks and then every 3 weeks up to 1 year or intolerance**
- **Outcomes :**
  - **Primary : Safety and Feasibility (CTC-AE 5.0)**
  - **Secondary : Progression free survival during chemotherapy holiday, duration of response, response under immunotherapy, duration of response under immunotherapy, response at chemo re-introduction, second PFS, overall survival, cellular immune response against neoepitopes, change in ctDNA**

Manufacturing : We make the complexity simple

Step 2

1 week+1 week

Sequencing and neo-antigens prediction

Samples sequencing

Genome Scan

Neo-antigen prediction

myNEO

Step 3

3-4 weeks

Personalized DNA manufacturing



Synthetic DNA

TOUCHLIGHT GENETICS

Step 4

Few days

Packaging

Packaging and labelling

NHS Blood and Transplant

MVA	***Anti CTLa4***

Produced in advance

odimma therapeutics

A Team with Strong Experience in Science, Product Development & Business

Jean-Marc Limacher, MD,
Co-Founder, President, CMO
Medical Oncologist & Cancer Geneticist

transgene · Hôpitaux Civils de Colmar

Pascale Balducchi, DVM, MBA,
Partner, CEO, CBO
Strategy & Business Partnering

Pierre Fabre · sanofi

Ronald Rooke, PhD,
Scientific Affairs
Immunologist

SERVIER

Rémi Gloeckler, PhD,
Pharmaceutical Development
Biologist

transgene · PHARMINCELL

Célia Matta, PhD,
Scientist
Biologist

Université de Strasbourg

Jérémy Amzallag, PharmD,
Qualified Person,
Head of Quality

EYLIO

Nicolas Ferry, MD,
Regulatory Affairs
Immunologist

Cécile Hugel,
Project Engineer
Biologist & Immunologist

Université de Strasbourg · igbmc

Company Profile

Odimma Therapeutics was founded in 2017.

Based in Strasbourg and Supported by Key Regional and National Players

Has been granted a Seal of Excellence by European Commission in 2024

Backed-up by an international advisory board

Timelines

2022 2023 2024 2025 2026 2027 2028 2029 2030

PoC in additional tumour models

GMP MVA manufacturing

GMP synthetic DNA processes development

Regulatory Scientific Advice Meeting (ANSM)

Toxicology study

Clinical Trial Application

Phase I

Phase IIa

Value proposition

Competitive advantages on different levels:
Science and Pharmaceutical Modalities



odimma
Active Personalized Immunotherapy

limacher@odimma-therapeutics.com

p.balducchi@odimma-therapeutics.com